Insilico's AI-discovered lung fibrosis drug enters Phase III
Rentosertib will test whether Insilico's end-to-end AI drug discovery thesis can survive late-stage clinical scrutiny.
By Ryan Merket ยท Published
Why it matters
Rentosertib's Phase III start moves AI drug discovery from platform marketing into a late-stage clinical test of whether an AI-originated target and molecule can produce durable patient benefit.
Insilico Medicine says its lead drug candidate, Rentosertib, has entered a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF), giving AI drug discovery a rare late-stage test. In its announcement, the company characterizes Rentosertib as the first "end-to-end AI-discovered" drug candidate to reach Phase III; that remains Insilico's claim and depends on how "end-to-end" is defined.
Rentosertib is an oral small-molecule inhibitor of TNIK (TRAF2- and NCK-interacting kinase). Insilico points to results from a randomized phase 2a trial in IPF published in Nature Medicine as support for advancing the program.
Why it matters for AI drug discovery
The practical question now is whether an AI-originated target-and-molecule story can translate into clinically meaningful efficacy and safety in a large, late-stage population. The field has spent years raising capital and signing partnerships on that premise. A Phase III readout will put less weight on platform claims and more on patient outcomes.
Status
Rentosertib remains investigational and has not been approved by regulators. Insilico continues to frame the program as an example of applying AI across discovery and development; Phase III is where that narrative meets the clinical bar that determines whether a drug helps patients with IPF.